Prevacus, Inc., a biopharmaceutical company headquartered in Tallahassee, Florida, that develops treatments for concussion (mild traumatic brain injury), and other neurological disorders, recently announced a new partnership with BrainScope, a medical-neurotechnology company located in Bethsda, Maryland, to use its BrainScope One device in an upcoming concussion study.
Prevacus, BrainScope Team Up to Study Concussions
1 min read Premium comments
Secondary#concussion#brainscope#Prevacus
Super Bowl MVP (Most Valuable Player) quarterbacks Brett Favre, Kurt Warner and Mark Rypien have also joined the two companies in their efforts to find a solution to concussions for youth and professional athletes.
The researchers in Prevacus’ upcoming Phase 1b drug study will use the FDA-cleared BrainScope One system to provide brain function assessment including EEG measures, cognitive performance tests, and standard, digitized concussion assessment tests. BrainScope’s Brain Function Index allows the researchers to objectively assess the functional injury component of the brain after an injury.
“BrainScope One will provide significant assistance during our upcoming Phase 1b study,” said Jake VanLandingham, Ph.D., chief executive officer of Prevacus in a press release. “We are grateful for their support in pursuit of discovering a solution to concussions for our athletes, military personnel and all other at-risk groups.”
Douglas Oberly, vice president, clinical affairs at BrainScope, added, “We are excited to see BrainScope One‘s capability being used to provide clinical data points to study Prevacus’ new and innovative drugs as an alternate line of therapies for traumatic brain injury.”
Prevacus, Inc. is developing a new drug (PRV-002) that treats concussion at the molecular level, reducing inflammation, swelling, ischemic injury and oxidative stress as well as restoring proper blood flow. PRV-002 is a fully synthetic non-naturally occurring neurosteroid administered through the nasal cavity.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.